Publication: Uso de Omalizumab en condiciones diferentes a las autorizadas
Loading...
Official URL
Full text at PDC
Publication Date
2015-06
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
El uso de medicamentos fuera de indicación (uso off-label) hace referencia al uso en condiciones distintas a las autorizadas en ficha técnica. Está avalado por estudios clínicos del fármaco con resultado satisfactorio para ese uso no aprobado. El Omalizumab es un anticuerpo monoclonal anti-IgE aprobado para el tratamiento del asma no controlada por otros tratamientos. En la práctica clínica actual se está usando también en patologías en las que la IgE está implicada, tales como la dermatitis atópica, la urticaria crónica, las alergias alimentarias y los casos de mastocitosis
The out of purpose use of medications (off-label) predispose to the use of those in different conditions than the ones approved in the licensed indication. It is underpinned by clinic trials of the medication with a satisfactory outcome for that unlicensed use. Omalizumab is a monoclonal antibody anti-IgE approved for the asthmatic treatment which is not controlled by other treatments. In the actual clinical practice, it is also used for IgE implicated pathologies, such as atopic dermatitis, chronic urticaria, food allergies and mastocytosis..
The out of purpose use of medications (off-label) predispose to the use of those in different conditions than the ones approved in the licensed indication. It is underpinned by clinic trials of the medication with a satisfactory outcome for that unlicensed use. Omalizumab is a monoclonal antibody anti-IgE approved for the asthmatic treatment which is not controlled by other treatments. In the actual clinical practice, it is also used for IgE implicated pathologies, such as atopic dermatitis, chronic urticaria, food allergies and mastocytosis..